HANGZHOU, China, Oct. 15 China Biopharma, Inc.(OTC Bulletin Board: CBPC) announced today that its partner, SoonfastPharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfullycompleted its trial production of a new antiviral product. This all-naturalmedicine has been approved in China for external use to treat humanpapillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown aninhibitory effect on the growth of HPV and HSV, and the medicine can reducethe infection from HPV and HSV up to 90% only in 2-3 days. Experiments havealso proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.The sample product is available for distributors now and the commercialproduct will be available next month.
HPV infection is common across all races and socio-economic groups and isprevalent throughout the world in sexually active persons. HPVs are the mostcommon sexually transmitted viral agents in the United States, infecting up to20% of people aged 15 to 49. In the last 30 years, the incidence of HPVinfection has increased dramatically. Despite the prevalence of HPV, noavailable drug therapy effectively eliminates HPV infection and replication orprevents HPV-associated malignant progression.
According to the agreement reached with Soonfast in June this year, ChinaBiopharma has the right to distribute this new all-natural antiviral medicinein overseas market. The successful trial production has now quickened someapproval process for China Biopharma to launch commercial sales on overseasmarket including Europe and the United States. The company and Soonfast alsoplan to jointly conduct studies on its extracts in both China and USA so as toobtain approval necessary for selling this medicine as an over-the-counterdrug. The company believes this new medicine would bring in significantrevenue and profit in the near future once it is successfully introduced intothe market.
About China Biopharma, Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based inChina. Through its operating subsidiaries, the company develops anddistributes biopharmaceutical and pharmaceutical products throughout theworld's most populated country, China. Products include human vaccines andother pharmaceutical drugs. Leveraging its investment and ownership of localChinese bio-pharmaceutical companies, and partnerships with internationalbiopharmaceutical companies, China Biopharma is building a highly-competitiveplatform for growth in China as well as new world markets, including the U.S.and Europe. For more information, visit its website athttp://www.chinabiopharma.net.
Safe Harbor Statement
Some of the statements here discuss future events and developments,including the Company's future business strategy and its ability to generaterevenue, income and cash flow, and should be considered forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. These "forward-looking" statements can generally be identified bywords such as "expect," "anticipate," "believe," "estimate," "intend," "plan,"and similar expressions. These statements involve a high degree of risk anduncertainty that exists in the Company's operations and business environmentand are subject to change based on various factors that could cause actualCompany results, performance, plans, goals and objectives to differ materiallyfrom those contemplated or implied in these forward-looking statements. Actualresults may be different from anticipated results for a number of reasons,including the Company's new and uncertain business model, uncertaintyregarding acceptance of the Company's products and services and the Company'slimited operating history.CONTACT: China Biopharma, Inc. Tel: +1 (609) 651-8588 Attn. George Ji [email protected]
SOURCE China Biopha